Hyperkalemia | Clinical Decision Support System for Quality Assurance in Potassium-Increasing Drug-Drug-Interactions
Hyperkalemia research study
What is the primary objective of this study?
To investigate the impact of reminders for serum potassium monitoring and of hyperkalemia alerts during potassium-increasing drug-drug-interactions.
Who is eligible to participate?
Inclusion criteria: - in-patients treated with concurrent potassium-increasing drugs Exclusion criteria: - outpatients; in-patients on wards without computerized physician order entry (i.e. patients treated in the ICU)
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Behavioral:decision support in potassium-inc. drug-drug-interactionsdisplay of computer-based reminders for serum potassium monitoring and hyperkalemia alerts
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
computer-based reminders and alertsBehavioral: display of computer-based reminders for serum potassium monitoring and hyperkalemia alerts (decision support in potassium-inc. drug-drug-interactions)
no computer-based reminders or alertsBehavioral: no display of computer-based reminders for serum potassium monitoring and hyperkalemia alerts
Start Date: January 2014
Completed Date: January 2015
Primary Outcome: Impact on serum potassium monitoring during potassium-increasing drug-drug-interactions
Secondary Outcome: Frequency of hyperkalemia during potassium-increasing drug-drug-interactions
Study sponsors, principal investigator, and references
Principal Investigator: Juerg Blaser, PhD, Prof
Lead Sponsor: University of Zurich
Eschmann E, Beeler PE, Kaplan V, Schneemann M, Zünd G, Blaser J. Patient- and physician-related risk factors for hyperkalaemia in potassium-increasing drug-drug interactions. Eur J Clin Pharmacol. 2014 Feb;70(2):215-23. doi: 10.1007/s00228-013-1597-2. Epub 2013 Oct 23.